Skip to main content

Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

The Original Article was published on 26 February 2021

Correction to: BMC Infect Dis 21, 222 (2021)

https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-05850-0

Following publication of the original article [1], the authors identified errors in Figs. 3a, b and 4. The correct figures are given below.

Fig. 3
figure1

Efficacy Results. a VS Risk Difference (RE model). b CD4 difference (FE model)

Fig. 4
figure2

Odds of all-cause discontinuation (FE model)

The original article has been corrected.

Reference

  1. 1.

    Nickel K, et al. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis. 2021;21:222. https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-05850-0.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yogesh Suresh Punekar.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nickel, K., Halfpenny, N.J.A., Snedecor, S.J. et al. Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis 21, 340 (2021). https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-06016-8

Download citation

\